271 related articles for article (PubMed ID: 31178408)
1. A Systems Pharmacology Approach Uncovers Wogonoside as an Angiogenesis Inhibitor of Triple-Negative Breast Cancer by Targeting Hedgehog Signaling.
Huang Y; Fang J; Lu W; Wang Z; Wang Q; Hou Y; Jiang X; Reizes O; Lathia J; Nussinov R; Eng C; Cheng F
Cell Chem Biol; 2019 Aug; 26(8):1143-1158.e6. PubMed ID: 31178408
[TBL] [Abstract][Full Text] [Related]
2. Wogonoside inhibits angiogenesis in breast cancer via suppressing Wnt/β-catenin pathway.
Huang Y; Zhao K; Hu Y; Zhou Y; Luo X; Li X; Wei L; Li Z; You Q; Guo Q; Lu N
Mol Carcinog; 2016 Nov; 55(11):1598-1612. PubMed ID: 26387984
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers.
Di Mauro C; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Formisano L; De Falco S; Cicatiello V; Di Bonito M; Cantile M; Collina F; Chambery A; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2017 May; 116(11):1425-1435. PubMed ID: 28441382
[TBL] [Abstract][Full Text] [Related]
4. Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis.
Lin B; Zhao K; Yang D; Bai D; Liao Y; Zhou Y; Yu Z; Yu X; Guo Q; Lu N
J Cell Physiol; 2019 Feb; 234(2):1913-1924. PubMed ID: 30105796
[TBL] [Abstract][Full Text] [Related]
5. An isoflavone derivative potently inhibits the angiogenesis and progression of triple-negative breast cancer by targeting the MTA2/SerRS/VEGFA pathway.
Zhang X; Zou G; Li X; Wang L; Xie T; Zhao J; Wang L; Jiao S; Xiang R; Ye H; Shi Y
Cancer Biol Med; 2020 Aug; 17(3):693-706. PubMed ID: 32944400
[No Abstract] [Full Text] [Related]
6. SANT, a novel Chinese herbal monomer combination, decreasing tumor growth and angiogenesis via modulating autophagy in heparanase overexpressed triple-negative breast cancer.
Li QW; Zhang GL; Hao CX; Ma YF; Sun X; Zhang Y; Cao KX; Li BX; Yang GW; Wang XM
J Ethnopharmacol; 2021 Feb; 266():113430. PubMed ID: 33011366
[TBL] [Abstract][Full Text] [Related]
7. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
8. Wogonoside inhibits lipopolysaccharide-induced angiogenesis in vitro and in vivo via toll-like receptor 4 signal transduction.
Chen Y; Lu N; Ling Y; Gao Y; Wang L; Sun Y; Qi Q; Feng F; Liu W; Liu W; You Q; Guo Q
Toxicology; 2009 May; 259(1-2):10-7. PubMed ID: 19428938
[TBL] [Abstract][Full Text] [Related]
9. Dipalmitoylphosphatidic acid inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1/FGF1/HGF signalling pathway.
Chen J; Zhou Z; Yao Y; Dai J; Zhou D; Wang L; Zhang QQ
J Cell Mol Med; 2018 Oct; 22(10):4760-4770. PubMed ID: 30010249
[TBL] [Abstract][Full Text] [Related]
10. Wogonoside induces growth inhibition and cell cycle arrest via promoting the expression and binding activity of GATA-1 in chronic myelogenous leukemia cells.
Li H; Hui H; Xu J; Yang H; Zhang X; Liu X; Zhou Y; Li Z; Guo Q; Lu N
Arch Toxicol; 2016 Jun; 90(6):1507-22. PubMed ID: 26104856
[TBL] [Abstract][Full Text] [Related]
11. Wogonoside induces apoptosis in human non-small cell lung cancer A549 cells by promoting mitochondria dysfunction.
Luo M; Mo J; Yu Q; Zhou S; Ning R; Zhang Y; Su C; Wang H; Cui J
Biomed Pharmacother; 2018 Oct; 106():593-598. PubMed ID: 29990847
[TBL] [Abstract][Full Text] [Related]
12. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer.
Zhang J; Liu C; Shi W; Yang L; Zhang Q; Cui J; Fang Y; Li Y; Ren G; Yang S; Xiang R
Oncotarget; 2016 Jul; 7(27):41067-41080. PubMed ID: 27203384
[TBL] [Abstract][Full Text] [Related]
13. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
[TBL] [Abstract][Full Text] [Related]
14. Wogonin inhibits tumor angiogenesis via degradation of HIF-1α protein.
Song X; Yao J; Wang F; Zhou M; Zhou Y; Wang H; Wei L; Zhao L; Li Z; Lu N; Guo Q
Toxicol Appl Pharmacol; 2013 Sep; 271(2):144-55. PubMed ID: 23707765
[TBL] [Abstract][Full Text] [Related]
15. Wogonoside inhibits tumor growth and metastasis in endometrial cancer via ER stress-Hippo signaling axis.
Chen S; Wu Z; Ke Y; Shu P; Chen C; Lin R; Shi Q
Acta Biochim Biophys Sin (Shanghai); 2019 Nov; 51(11):1096-1105. PubMed ID: 31696210
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
[TBL] [Abstract][Full Text] [Related]
17. Stem-like tumor cells involved in heterogeneous vasculogenesis in breast cancer.
Mao Y; Zhu L; Huang Z; Luo C; Zhou T; Li L; Wang G; Yang Z; Qi W; Yang X; Gao G
Endocr Relat Cancer; 2020 Jan; 27(1):23-39. PubMed ID: 31705798
[TBL] [Abstract][Full Text] [Related]
18. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
[TBL] [Abstract][Full Text] [Related]
20. Salidroside inhibits migration, invasion and angiogenesis of MDA‑MB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2.
Kang DY; Sp N; Kim DH; Joung YH; Lee HG; Park YM; Yang YM
Int J Oncol; 2018 Aug; 53(2):877-885. PubMed ID: 29901185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
